Brokerages Set RAPT Therapeutics, Inc. (NASDAQ:RAPT) PT at $25.67

Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) have been assigned an average recommendation of “Moderate Buy” from the twelve analysts that are covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $25.67.

Several research analysts recently commented on RAPT shares. Barclays cut their price target on shares of RAPT Therapeutics from $35.00 to $13.00 and set an “overweight” rating on the stock in a report on Wednesday, February 21st. JPMorgan Chase & Co. reduced their target price on shares of RAPT Therapeutics from $15.00 to $13.00 and set a “neutral” rating on the stock in a report on Wednesday, March 27th. Cantor Fitzgerald cut shares of RAPT Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Tuesday, February 20th. Evercore ISI began coverage on RAPT Therapeutics in a research report on Friday, February 16th. They issued an “outperform” rating on the stock. Finally, SVB Leerink downgraded RAPT Therapeutics from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $42.00 to $10.00 in a research report on Wednesday, February 21st.

RAPT Therapeutics Stock Up 6.2 %

RAPT stock opened at $8.18 on Monday. RAPT Therapeutics has a 52 week low of $6.86 and a 52 week high of $27.35. The company has a market cap of $284.66 million, a price-to-earnings ratio of -2.69 and a beta of 0.47. The business has a fifty day simple moving average of $8.49 and a 200-day simple moving average of $15.39.

RAPT Therapeutics (NASDAQ:RAPT) last announced its quarterly earnings results on Thursday, March 7th. The company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.05. As a group, analysts expect that RAPT Therapeutics will post -3.19 earnings per share for the current fiscal year.

Institutional Investors Weigh In On RAPT Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of RAPT. Swiss National Bank grew its position in shares of RAPT Therapeutics by 9.6% during the third quarter. Swiss National Bank now owns 49,100 shares of the company’s stock worth $816,000 after buying an additional 4,300 shares in the last quarter. FMR LLC grew its holdings in RAPT Therapeutics by 7.4% during the 3rd quarter. FMR LLC now owns 4,499,293 shares of the company’s stock worth $74,778,000 after acquiring an additional 308,804 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of RAPT Therapeutics by 347.8% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,981 shares of the company’s stock worth $99,000 after purchasing an additional 3,092 shares during the last quarter. Braidwell LP raised its stake in shares of RAPT Therapeutics by 10.0% in the 3rd quarter. Braidwell LP now owns 1,082,512 shares of the company’s stock valued at $17,991,000 after purchasing an additional 98,112 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of RAPT Therapeutics by 3.9% during the third quarter. Vanguard Group Inc. now owns 2,023,305 shares of the company’s stock worth $33,627,000 after purchasing an additional 76,356 shares during the last quarter. 99.09% of the stock is currently owned by hedge funds and other institutional investors.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.